

Basic Results Summary

A study in healthy volunteers to evaluate the effect of repeated LPS skin challenges in a single individual

CHDR number: CHDR2336


Sponsor: F. Hoffmann-La Roche Ltd

ISRCTN number: ISRCTN13536369

Table of Contents

Participant flow	3
Baseline characteristics	4
Primary outcome measures	5
1. Safety	5
1.1. <i>Treatment-emergent (serious) adverse events ((S)AEs)</i>	5
1.2. <i>Safety labs tests (acute phase proteins (CRP), leukocyte differentiation)</i>	5
1.3. <i>Vital signs (Heart rate, Blood pressure)</i>	12
2. Dermal imaging/scoring.....	14
2.1. <i>Perfusion by Laser Speckle Contrast Imaging (LSCI)</i>	14
2.2. <i>Erythema by Antera 3D camera</i>	17
2.3. <i>Erythema grading score: Clinical Erythema Assessment (CEA)</i>	19
3. Blister exudate analysis.....	20
3.1. <i>Neutrophils and monocyte subsets</i>	20
Adverse events	24

Participant flow



*One participant remained part of the PD population but is excluded from the PD summary and analysis due to an adverse event, unrelated to the lipopolysaccharide, leading to discontinuation.

Baseline characteristics

	ENROLLED SUBJECTS (N=9)
Age (years)	
n	9
Mean (SD)	23.8 (2.8)
Median	25
Min, Max	19, 27
Height (cm)	
n	9
Mean (SD)	180.86 (8.82)
Median	176.0
Min, Max	167.5, 193.0
Weight (kg)	
n	9
Mean (SD)	76.94 (13.21)
Median	79.40
Min, Max	58.15, 93.85
BMI (kg/m^2)	
n	9
Mean (SD)	23.37 (2.42)
Median	22.8
Min, Max	20.7, 26.9
Sex	
Female	2 (22.2%)
Male	7 (77.8%)
Race	
WHITE	9 (100.0%)

Primary outcome measures

1. Safety

NB: The NRS pain assessment was performed on Day 1 for the arm and on 1 area on the back, but was not evaluated in comparison to the other LPS challenge sets. As it was not included in the SAP listings and summaries, no output is available.

1.1. Treatment-emergent (serious) adverse events ((S)AEs).

Please refer to the section [Adverse events](#).

1.2. Safety labs tests (acute phase proteins (CRP), leukocyte differentiation)

Summary of C-Reactive Protein (CRP) Results																
Parameter (Unit)	Treatment	Visit	Result							Change from baseline						
			N	mean	SEM	SD	median	min*	max	N	mean	SEM	SD	median	min	max
High-Sensitivity C Reactive Protein (mg/L)	LIPOPOLYSAC CHARIDE CHALLENGE 1	DAY 1	9	0.5211	0.28862	0.86587	0.190	0.075	2.660	0						
		DAY 2	9	1.0283	0.39396	1.18187	0.580	0.075	3.850	9	0.5072	0.16191	0.48572	0.300	0.000	1.380
	LIPOPOLYSAC CHARIDE CHALLENGE 2	DAY 1	8	0.6900	0.32282	0.91308	0.235	0.075	2.740	0						
		DAY 2	8	1.1419	0.78399	2.21746	0.225	0.075	6.570	8	0.4519	0.48317	1.36662	-0.010	-0.160	3.830
	LIPOPOLYSAC CHARIDE CHALLENGE 3	DAY 1	8	1.0050	0.48893	1.38290	0.325	0.075	3.480	0						
		DAY 2	8	1.9256	1.09880	3.10788	0.480	0.075	8.300	8	0.9206	0.62353	1.76362	0.080	-0.175	4.820
NO_TRT	SCREENING	9	0.5717	0.32771	0.98314	0.230	0.075	3.150								
	FOLLOW-UP	9	1.0244	0.34144	1.02432	0.680	0.075	2.760								

NO_TRT: No treatment

*According to the SAP, safety and PD values below the Limit of Quantification (LOQ) are set to half of the LOQ for summary outputs. As the LOQ for High-Sensitivity C-Reactive Protein is 0.15, the corresponding value used here is 0.075.

Summary of Leukocytes Results																	
Parameter (Unit)	Treatment	Visit	Analysis Timepoint	Result							Change from baseline						
				N	mean	SEM	SD	median	min	max	N	mean	SEM	SD	median	min	max
Leukocytes (10^9/L)	LIPOPOLYSAC CHARIDE CHALLENGE 1	DAY 1	-00D00H36M	9	4.911	0.4361	1.3082	4.85	3.36	7.88	0	0.173	0.1384	0.4153	0.23	-0.58	0.65
			00D01H55M	9	5.084	0.4581	1.3743	4.87	3.35	7.82	9						
		DAY 2	00D03H55M	9	8.962	1.0966	3.2899	8.07	4.88	14.96	9	4.051	0.7725	2.3174	4.21	0.99	7.16
			00D09H34M	9	7.233	0.5510	1.6530	6.62	5.63	10.02	9	2.322	0.2703	0.8109	2.13	1.35	4.05
			00D23H36M	9	4.677	0.3882	1.1647	4.39	3.18	6.89	9	-0.234	0.1353	0.4059	-0.18	-0.99	0.45
	LIPOPOLYSAC CHARIDE CHALLENGE 2	DAY 1	-00D00H30M	8	4.704	0.3044	0.8610	4.79	2.86	5.68	0	0.613	0.1713	0.4845	0.66	-0.17	1.31
			00D01H58M	8	5.316	0.3261	0.9223	5.53	3.56	6.30	8						
		DAY 2	00D03H58M	7	6.241	0.3022	0.7995	6.44	5.07	7.16	7	1.677	0.2313	0.6119	1.70	0.64	2.54
			00D09H43M	8	6.438	0.3285	0.9292	6.26	5.29	7.81	8	1.734	0.3485	0.9856	1.97	-0.14	2.76
			00D23H43M	8	4.725	0.3023	0.8549	4.91	3.05	5.96	8	0.021	0.0637	0.1801	0.01	-0.18	0.28
	LIPOPOLYSAC CHARIDE CHALLENGE 3	DAY 1	-00D00H30M	8	4.754	0.3725	1.0536	4.59	3.13	6.64	0	0.433	0.2788	0.7885	0.13	-0.41	1.76
			00D01H58M	8	5.186	0.5405	1.5288	4.84	3.21	8.40	8						
		DAY 2	00D03H58M	8	6.528	0.7221	2.0425	6.12	4.12	10.01	8	1.774	0.5227	1.4785	1.23	0.46	4.82
			00D09H43M	8	6.459	0.3950	1.1172	6.18	5.01	8.37	8	1.705	0.2571	0.7273	1.64	0.80	2.92
			00D23H43M	8	4.378	0.3743	1.0586	4.55	2.89	6.27	8	-0.376	0.1721	0.4867	-0.42	-0.94	0.43
NO_TRT	SCREENING	SCR		9	5.272	0.5698	1.7093	4.88	3.14	9.04							
	FOLLOW-UP		37D00H00M	9	5.719	0.7958	2.3873	4.84	3.69	9.90							

NO_TRT: No treatment

Summary of Lymphocytes Results																	
Parameter (Unit)	Treatment	Visit	Analysis Timepoint	Result						Change from baseline							
				N	mean	SEM	SD	median	min	max	N	mean	SEM	SD	median	min	max
Lymphocytes (10^9/L)	LIPOPOLYSAC CHARIDE CHALLENGE 1	DAY 1	-00D00H36M	9	1.822	0.1529	0.4588	1.81	1.12	2.54	0	-0.107	0.1010	0.3030	-0.13	-0.54	0.30
			00D01H55M	9	1.716	0.1266	0.3797	1.76	1.02	2.11	9						
			00D03H55M	9	1.791	0.1499	0.4498	1.95	1.00	2.37	9	-0.031	0.1150	0.3450	0.03	-0.52	0.56
		DAY 2	00D09H34M	9	2.102	0.1451	0.4354	2.31	1.24	2.72	9		0.280	0.0746	0.2238	0.28	-0.02
			00D23H36M	9	1.533	0.1262	0.3786	1.44	1.03	2.19	9	-0.289	0.0804	0.2412	-0.35	-0.57	0.17
	LIPOPOLYSAC CHARIDE CHALLENGE 2	DAY 1	-00D00H30M	8	1.728	0.1581	0.4472	1.79	1.00	2.29	0	-0.019	0.1399	0.3957	0.08	-0.57	0.45
			00D01H58M	8	1.709	0.1653	0.4676	1.64	1.17	2.66	8		0.084	0.1278	0.3381	0.13	-0.35
			00D03H58M	7	1.884	0.1908	0.5048	1.90	1.13	2.78	7	0.209	0.1119	0.3166	0.18	-0.23	0.63
		DAY 2	00D09H43M	8	1.936	0.1952	0.5522	1.97	1.08	2.92	8		0.1174	0.3319	-0.02	-0.79	0.21
			00D23H43M	8	1.569	0.1337	0.3783	1.60	0.99	2.17	8	-0.159	0.1174	0.3319	-0.02	-0.79	0.21
	LIPOPOLYSAC CHARIDE CHALLENGE 3	DAY 1	-00D00H30M	8	1.628	0.0705	0.1994	1.62	1.41	1.97	0	0.079	0.1353	0.3826	0.03	-0.53	0.65
			00D01H58M	8	1.706	0.1318	0.3728	1.73	1.14	2.28	8		0.041	0.1328	0.3755	0.05	-0.49
			00D03H58M	8	1.669	0.1151	0.3255	1.56	1.15	2.13	8	0.283	0.1323	0.3742	0.25	-0.27	0.74
		DAY 2	00D09H43M	8	1.910	0.1332	0.3768	1.87	1.43	2.44	8		0.0781	0.2208	-0.11	-0.42	0.23
			00D23H43M	8	1.496	0.0875	0.2475	1.55	1.06	1.81	8	-0.131	0.0781	0.2208	-0.11	-0.42	0.23
NO_TRT	SCREENING	SCR		9	1.798	0.1847	0.5542	1.70	1.06	2.65							
	FOLLOW-UP		37D00H00M	9	1.720	0.1714	0.5142	1.68	1.13	2.55							

NO_TRT: No treatment

Summary of Monocytes Results																	
Parameter (Unit)	Treatment	Visit	Analysis Timepoint	Result						Change from baseline							
				N	mean	SEM	SD	median	min	max	N	mean	SEM	SD	median	min	max
Monocytes (10^9/L)	LIPOPOLYSAC CHARIDE CHALLENGE 1	DAY 1	-00D00H36M	9	0.427	0.0437	0.1311	0.39	0.30	0.72	0	-0.009	0.0250	0.0749	0.00	-0.12	0.14
			00D01H55M	9	0.418	0.0542	0.1627	0.39	0.20	0.75	9						
		DAY 2	00D03H55M	9	0.662	0.0854	0.2563	0.63	0.36	1.25	9	0.236	0.0499	0.1496	0.29	0.04	0.53
			00D09H34M	9	0.556	0.0631	0.1894	0.58	0.29	0.92	9	0.129	0.0286	0.0857	0.15	-0.03	0.23
			00D23H36M	9	0.377	0.0468	0.1405	0.34	0.24	0.70	9	-0.050	0.0134	0.0403	-0.06	-0.11	0.01
	LIPOPOLYSAC CHARIDE CHALLENGE 2	DAY 1	-00D00H30M	8	0.389	0.0416	0.1178	0.36	0.23	0.56	0	0.035	0.0155	0.0438	0.02	-0.01	0.12
			00D01H58M	8	0.424	0.0477	0.1348	0.38	0.30	0.66	8						
		DAY 2	00D03H58M	7	0.473	0.0435	0.1150	0.45	0.35	0.69	7	0.109	0.0273	0.0722	0.08	0.02	0.22
			00D09H43M	8	0.479	0.0388	0.1099	0.45	0.37	0.68	8	0.090	0.0252	0.0713	0.07	0.01	0.19
			00D23H43M	8	0.385	0.0231	0.0652	0.38	0.31	0.46	8	-0.004	0.0217	0.0614	0.01	-0.10	0.08
	LIPOPOLYSAC CHARIDE CHALLENGE 3	DAY 1	-00D00H30M	8	0.410	0.0423	0.1195	0.38	0.24	0.58	0	0.036	0.0271	0.0767	0.02	-0.08	0.16
			00D01H58M	8	0.446	0.0518	0.1465	0.43	0.25	0.67	8						
		DAY 2	00D03H58M	8	0.515	0.0756	0.2139	0.51	0.26	0.85	8	0.105	0.0390	0.1102	0.08	-0.03	0.27
			00D09H43M	8	0.496	0.0426	0.1206	0.53	0.30	0.62	8	0.086	0.0237	0.0670	0.11	-0.03	0.17
			00D23H43M	8	0.376	0.0477	0.1348	0.36	0.20	0.57	8	-0.034	0.0293	0.0830	-0.02	-0.20	0.06
NO_TRT	SCREENING	SCR		9	0.473	0.0661	0.1984	0.44	0.28	0.91							
	FOLLOW-UP	37D00H00M		9	0.478	0.0693	0.2080	0.41	0.26	0.94							

NO_TRT: No treatment

Summary of Neutrophils Results																			
Parameter (Unit)	Treatment	Visit	Analysis Timepoint	Result								Change from baseline							
				N	mean	SEM	SD	median	min	max	N	mean	SEM	SD	median	min	max		
Neutrophils (10^9/L)	LIPOPOLYSAC CHARIDE CHALLENGE 1	DAY 1	-00D00H36M	9	2.420	0.2757	0.8271	2.22	1.75	4.43	0	0.317	0.1265	0.3794	0.24	-0.10	1.23		
			00D01H55M	9	2.737	0.3127	0.9380	2.29	1.85	4.67	9								
		DAY 2	00D03H55M	9	6.277	0.9761	2.9283	5.79	2.68	11.29	9	3.857	0.7622	2.2865	3.57	0.87	6.97		
			00D09H34M	9	4.322	0.4333	1.2999	3.90	2.67	6.40	9	1.902	0.2748	0.8245	1.79	0.72	3.43		
			00D23H36M	9	2.531	0.2566	0.7698	2.43	1.75	4.11	9	0.111	0.0780	0.2340	0.20	-0.32	0.50		
	LIPOPOLYSAC CHARIDE CHALLENGE 2	DAY 1	-00D00H30M	8	2.403	0.2394	0.6770	2.28	1.51	3.68	0	0.612	0.1500	0.4242	0.49	0.04	1.41		
			00D01H58M	8	3.015	0.2087	0.5903	3.04	2.03	3.98	8								
		DAY 2	00D03H58M	7	3.693	0.2152	0.5694	3.75	2.97	4.40	7	1.473	0.2390	0.6323	1.40	0.82	2.45		
			00D09H43M	8	3.790	0.2057	0.5818	3.73	3.08	4.76	8	1.388	0.3653	1.0333	1.55	-0.45	2.81		
			00D23H43M	8	2.576	0.2822	0.7982	2.65	1.57	4.05	8	0.174	0.1159	0.3277	0.19	-0.38	0.67		
	LIPOPOLYSAC CHARIDE CHALLENGE 3	DAY 1	-00D00H30M	8	2.513	0.3273	0.9256	2.41	1.31	4.39	0	0.344	0.1507	0.4263	0.27	-0.10	1.17		
			00D01H58M	8	2.856	0.4298	1.2155	2.71	1.64	5.56	8								
		DAY 2	00D03H58M	8	4.128	0.5979	1.6911	3.91	2.20	7.31	8	1.615	0.4416	1.2491	1.27	0.39	4.37		
			00D09H43M	8	3.854	0.3356	0.9492	3.75	2.49	5.60	8	1.341	0.1733	0.4901	1.36	0.68	2.02		
			00D23H43M	8	2.330	0.2911	0.8233	2.40	1.26	3.81	8	-0.183	0.1537	0.4348	-0.20	-0.86	0.35		
NO_TRT	SCREENING	SCR		9	2.761	0.3344	1.0031	2.53	1.66	4.99									
	FOLLOW-UP	37D00H00M		9	3.326	0.5625	1.6876	2.75	1.81	6.35									

NO_TRT: No treatment

Summary of Basophils Results																	
Parameter (Unit)	Treatment	Visit	Analysis Timepoint	Result							Change from baseline						
				N	mean	SEM	SD	median	min	max	N	mean	SEM	SD	median	min	max
Basophils (10^9/L)	LIPOPOLYSAC CHARIDE CHALLENGE 1	DAY 1	-00D00H36M	9	0.047	0.0058	0.0173	0.05	0.02	0.07	0	0.000	0.0033	0.0100	0.00	-0.01	0.01
			00D01H55M	9	0.047	0.0062	0.0187	0.05	0.02	0.08	9	-0.001	0.0031	0.0093	0.00	-0.02	0.01
		DAY 2	00D03H55M	9	0.046	0.0058	0.0174	0.04	0.03	0.07	9	0.001	0.0039	0.0117	0.00	-0.02	0.02
			00D09H34M	9	0.048	0.0072	0.0217	0.04	0.02	0.09	9	-0.007	0.0037	0.0112	0.00	-0.02	0.01
			00D23H36M	9	0.040	0.0041	0.0122	0.04	0.02	0.06	9	0.006	0.0018	0.0052	0.01	0.00	0.01
	LIPOPOLYSAC CHARIDE CHALLENGE 2	DAY 1	-00D00H30M	8	0.033	0.0059	0.0167	0.03	0.01	0.06	0	0.006	0.0018	0.0052	0.01	0.00	0.01
			00D01H58M	8	0.039	0.0064	0.0181	0.04	0.02	0.07	8	0.016	0.0020	0.0053	0.02	0.01	0.02
		DAY 2	00D03H58M	7	0.049	0.0086	0.0227	0.05	0.02	0.08	7	0.009	0.0040	0.0113	0.01	0.00	0.03
			00D09H43M	8	0.041	0.0052	0.0146	0.04	0.03	0.07	8	0.006	0.0018	0.0052	0.01	0.00	0.01
			00D23H43M	8	0.039	0.0052	0.0146	0.04	0.02	0.06	8	0.006	0.0018	0.0052	0.01	0.00	0.01
	LIPOPOLYSAC CHARIDE CHALLENGE 3	DAY 1	-00D00H30M	8	0.033	0.0037	0.0104	0.03	0.02	0.05	0	0.006	0.0032	0.0092	0.00	0.00	0.02
			00D01H58M	8	0.039	0.0052	0.0146	0.04	0.02	0.06	8	0.013	0.0037	0.0104	0.01	0.00	0.03
		DAY 2	00D03H58M	8	0.045	0.0057	0.0160	0.05	0.02	0.07	8	0.006	0.0046	0.0130	0.01	-0.01	0.02
			00D09H43M	8	0.039	0.0048	0.0136	0.04	0.02	0.06	8	0.004	0.0038	0.0106	0.01	-0.01	0.02
			00D23H43M	8	0.036	0.0053	0.0151	0.04	0.01	0.05	8	0.004	0.0038	0.0106	0.01	-0.01	0.02
NO_TRT	SCREENING	SCR		9	0.042	0.0066	0.0199	0.04	0.02	0.08							
	FOLLOW-UP		37D00H00M	9	0.042	0.0057	0.0172	0.04	0.02	0.08							

NO_TRT: No treatment.

Summary of Eosinophils Results																	
Parameter (Unit)	Treatment	Visit	Analysis Timepoint	Result						Change from baseline							
				N	mean	SEM	SD	median	min	max	N	mean	SEM	SD	median	min	max
Eosinophils (10^9/L)	LIPOPOLYSAC CHARIDE CHALLENGE 1	DAY 1	-00D00H36M	9	0.196	0.0320	0.0961	0.20	0.07	0.34	0	-0.028	0.0121	0.0363	-0.02	-0.08	0.02
			00D01H55M	9	0.168	0.0324	0.0971	0.14	0.03	0.33	9						
		DAY 2	00D03H55M	9	0.187	0.0369	0.1106	0.19	0.05	0.38	9	-0.009	0.0166	0.0499	0.00	-0.11	0.07
			00D09H34M	9	0.206	0.0376	0.1127	0.24	0.05	0.38	9	0.010	0.0149	0.0447	0.00	-0.07	0.07
			00D23H36M	9	0.196	0.0379	0.1136	0.20	0.04	0.42	9	0.000	0.0181	0.0543	-0.01	-0.08	0.11
	LIPOPOLYSAC CHARIDE CHALLENGE 2	DAY 1	-00D00H30M	8	0.153	0.0323	0.0915	0.15	0.05	0.31	0	-0.023	0.0124	0.0349	-0.02	-0.07	0.03
			00D01H58M	8	0.130	0.0266	0.0752	0.11	0.04	0.25	8						
		DAY 2	00D03H58M	7	0.143	0.0341	0.0901	0.10	0.06	0.31	7	-0.004	0.0107	0.0282	0.00	-0.06	0.02
			00D09H43M	8	0.191	0.0406	0.1147	0.18	0.06	0.44	8	0.039	0.0161	0.0455	0.04	-0.03	0.13
			00D23H43M	8	0.156	0.0343	0.0971	0.15	0.03	0.34	8	0.004	0.0096	0.0272	0.01	-0.03	0.04
	LIPOPOLYSAC CHARIDE CHALLENGE 3	DAY 1	-00D00H30M	8	0.171	0.0282	0.0799	0.19	0.05	0.25	0	-0.033	0.0096	0.0271	-0.03	-0.08	0.00
			00D01H58M	8	0.139	0.0218	0.0617	0.16	0.05	0.22	8						
		DAY 2	00D03H58M	8	0.171	0.0324	0.0916	0.17	0.03	0.28	8	0.000	0.0141	0.0400	0.01	-0.07	0.06
			00D09H43M	8	0.160	0.0237	0.0670	0.16	0.05	0.24	8	-0.011	0.0152	0.0429	0.00	-0.09	0.04
		DAY 2	00D23H43M	8	0.139	0.0232	0.0656	0.15	0.04	0.21	8	-0.033	0.0124	0.0349	-0.04	-0.09	0.01
NO_TRT	SCREENING	SCR		9	0.198	0.0454	0.1363	0.19	0.06	0.42							
	FOLLOW-UP		37D00H00M	9	0.153	0.0336	0.1009	0.17	0.03	0.29							

NO_TRT: No treatment

1.3. Vital signs (Heart rate, Blood pressure)

Summary of Vital Signs																		
Parameter (Unit)	Treatment	Visit	Timepoint	Result								Change from baseline						
				N	mean	SEM	SD	median	min	max	N	mean	SEM	SD	median	min	max	
Systolic Blood Pressure (mmHg)	LIPOPOLYSACC HARIDE CHALLENGE 1	DAY 1	-00D00H57M	9	121.8	3.61	10.84	122	104	139	0	-5.6	2.37	7.11	-7	-15	10	
			00D01H53M	9	116.2	4.71	14.14	115	89	136	9	-0.1	2.00	5.99	2	-8	7	
			00D03H53M	9	121.7	2.73	8.20	123	111	133	9	-2.1	1.59	4.76	-1	-10	5	
			00D09H33M	9	119.7	2.86	8.59	121	105	130	9	-7.2	2.13	6.38	-6	-21	1	
		DAY 2	00D23H36M	9	114.6	2.29	6.88	118	104	123	9							
	LIPOPOLYSACC HARIDE CHALLENGE 2	DAY 2	LIPOPOLYSACC DAY 1	8	115.1	3.91	11.06	117	95	130	0							
			00D09H42M	8	112.9	4.83	13.66	114	94	137	8	-2.3	2.08	5.87	-2	-13	7	
			00D23H43M	8	111.1	4.74	13.40	112	94	135	8	-4.0	3.52	9.94	-2	-23	7	
	LIPOPOLYSACC HARIDE CHALLENGE 3	DAY 2	LIPOPOLYSACC DAY 1	8	112.9	4.57	12.93	112	95	133	0							
			00D09H42M	8	118.6	5.61	15.86	118	96	143	8	5.8	3.00	8.48	5	-6	21	
			00D23H41M	8	113.6	3.29	9.32	113	100	131	8	0.8	2.58	7.29	2	-16	7	
Diastolic Blood Pressure (mmHg)	NO_TRT	SCREENING FOLLOW-UP	NO_TRT SCREENING FOLLOW-UP	SCR	118.1	3.40	10.19	118	103	137								
			37D00H00M	9	114.9	4.22	12.65	116	92	134								
			LIPOPOLYSACC HARIDE CHALLENGE 1	-00D00H57M	9	67.1	1.99	5.97	66	57	74	0						
				00D01H53M	9	66.4	3.07	9.22	67	49	80	9	-0.7	1.49	4.47	-2	-8	6
				00D03H53M	9	64.7	2.03	6.10	65	54	75	9	-2.4	1.46	4.39	-1	-10	2
				00D09H33M	9	65.9	1.76	5.28	65	56	73	9	-1.2	1.28	3.83	-1	-9	5
			DAY 2	00D23H36M	9	63.4	2.11	6.33	62	52	76	9	-3.7	1.93	5.79	-5	-12	5
	LIPOPOLYSACC HARIDE CHALLENGE 2	DAY 2	LIPOPOLYSACC DAY 1	-00D00H49M	8	62.4	2.57	7.27	62	51	73	0						
			00D09H42M	8	59.1	1.61	4.55	59	54	68	8	-3.3	1.50	4.23	-4	-11	3	
			00D23H43M	8	60.1	1.97	5.57	59	55	70	8	-2.3	2.01	5.68	-2	-12	5	
	LIPOPOLYSACC HARIDE CHALLENGE 3	DAY 2	LIPOPOLYSACC DAY 1	-00D00H49M	8	65.1	4.25	12.02	59	55	83	0						
			00D09H42M	8	63.8	2.59	7.32	65	54	72	8	-1.4	2.83	8.00	-2	-11	13	
			00D23H41M	8	62.3	3.03	8.56	63	50	76	8	-2.9	2.22	6.27	-4	-11	7	
Heart Rate (beats/min)	NO_TRT	SCREENING FOLLOW-UP	NO_TRT SCREENING FOLLOW-UP	SCR	65.0	2.21	6.63	65	55	76								
			37D00H00M	9	62.1	2.46	7.37	59	55	75								
			LIPOPOLYSACC HARIDE CHALLENGE 1	-00D00H57M	9	64.9	3.12	9.35	62	53	79	0						
				00D01H53M	9	53.8	2.17	6.50	56	44	62	9	-11.1	4.80	14.41	-7	-34	5
				00D03H53M	9	58.3	2.23	6.69	61	46	67	9	-6.6	4.03	12.09	-3	-31	8
			DAY 2	00D09H33M	9	60.8	1.92	5.76	62	53	69	9	-4.1	3.71	11.12	0	-24	7
			00D23H36M	9	61.1	3.78	11.34	65	44	73	9	-3.8	4.70	14.10	-4	-29	15	
	LIPOPOLYSACC HARIDE CHALLENGE 2	DAY 2	LIPOPOLYSACC DAY 1	-00D00H49M	8	58.0	2.91	8.23	58	48	67	0						
			00D09H42M	8	62.9	3.23	9.14	65	50	75	8	4.9	1.82	5.14	6	-3	13	
			00D23H43M	8	61.1	2.29	6.49	60	54	72	8	3.1	2.64	7.45	4	-10	15	

CHDR2336 Basic Results Summary

	LIPOPOLYSACC DAY 1	-00D00H49M	8	63.0	2.92	8.25	64	48	74	0	1.1	3.91	11.05	-1	-15	19	
HARIDE		00D09H42M	8	64.1	3.01	8.53	63	47	75	8	-6.3	3.93	11.12	-8	-20	13	
CHALLENGE 3	DAY 2	00D23H41M	8	56.8	2.45	6.92	59	42	62	8							
NO_TRT	SCREENING	SCR	9	57.9	3.18	9.53	55	47	76								
Heart Rate (beats/min)	NO_TRT	FOLLOW-UP	37D00H00M	9	59.3	3.46	10.37	63	47	76							
Temperatu re (C)	LIPOPOLYSACC DAY 1	-00D00H56M	9	36.58	0.085	0.254	36.6	36.2	37.0	0	0.12	0.121	0.363	0.2	-0.5	0.6	
HARIDE		00D01H54M	9	36.70	0.107	0.320	36.8	35.9	37.0	9	0.31	0.105	0.314	0.3	-0.1	0.8	
CHALLENGE 1		00D03H54M	9	36.89	0.115	0.344	36.9	36.3	37.5	9	0.13	0.071	0.212	0.1	-0.1	0.6	
	DAY 2	00D23H36M	9	36.71	0.081	0.242	36.7	36.3	37.0	9							
LIPOPOLYSACC DAY 1		-00D00H48M	8	36.66	0.098	0.277	36.7	36.3	37.1	0	0.15	0.105	0.298	0.1	-0.4	0.5	
HARIDE		00D01H57M	8	36.81	0.122	0.344	36.8	36.3	37.4	8	0.00	0.060	0.169	0.0	-0.2	0.2	
CHALLENGE 2		00D03H57M	8	36.66	0.100	0.283	36.7	36.2	37.2	8	0.19	0.162	0.458	0.3	-0.7	0.8	
	DAY 2	00D23H43M	8	36.85	0.180	0.510	36.9	36.1	37.6	8							
LIPOPOLYSACC DAY 1		-00D00H48M	8	36.59	0.149	0.422	36.5	36.1	37.3	0	0.19	0.064	0.181	0.2	-0.1	0.4	
HARIDE		00D01H57M	8	36.78	0.132	0.373	36.6	36.4	37.4	8	0.25	0.057	0.160	0.3	0.0	0.5	
CHALLENGE 3		00D03H57M	8	36.84	0.122	0.346	36.9	36.3	37.3	8	0.18	0.118	0.333	0.1	-0.3	0.6	
	DAY 2	00D23H42M	8	36.76	0.167	0.472	37.1	36.1	37.2	8							
NO_TRT	SCREENING	SCR	9	36.62	0.068	0.205	36.6	36.4	37.1								
	FOLLOW-UP	37D00H00M	9	36.66	0.116	0.347	36.6	36.2	37.3								

NO_TRT: No treatment

2. Dermal imaging/scoring

2.1. Perfusion by Laser Speckle Contrast Imaging (LSCI)

Effect/Contrast	P-value	Analysis results LSCI Flare-1 Mean (AU)				95% CI	
		First LSM of contrast	Second LSM of contrast	Estimate of the difference	Lower	Upper	
Prevalue	0.0003						
LPS Challenge Day	0.1523						
Time	<.0001						
Day by time	0.0157						
LPS Day 15 - LPS Day 1	0.2565	114.0	118.8	-4.7	-13.3	3.9	
LPS Day 29 - LPS Day 1	0.0547	110.9	118.8	-7.9	-16.0	0.2	
LPS Day 29 - LPS Day 15	0.3425	110.9	114.0	-3.2	-10.2	3.8	
LPS Day 15 - LPS Day 1 at 10h	0.9799	121.0	121.2	-0.1	-10.3	10.1	
LPS Day 29 - LPS Day 1 at 10h	0.5173	118.0	121.2	-3.1	-12.9	6.6	
LPS Day 29 - LPS Day 15 at 10h	0.4671	118.0	121.0	-3.0	-11.3	5.3	
LPS Day 15 - LPS Day 1 at 24h	0.9236	109.1	108.7	0.5	-9.7	10.7	
LPS Day 29 - LPS Day 1 at 24h	0.5354	105.7	108.7	-3.0	-12.7	6.8	
LPS Day 29 - LPS Day 15 at 24h	0.4005	105.7	109.1	-3.5	-11.8	4.8	
95% CI							
Treatment	Time	LSM	Lower	Upper	LSM change from baseline	Lower	Upper
LPS Day 1	Overall	118.8	111.4	126.1	29.5	22.1	36.8
	2h	121.2	112.9	129.5	31.9	23.6	40.2
	4h	124.0	115.7	132.3	34.7	26.4	43.0
	10h	121.2	112.9	129.4	31.9	23.6	40.1
	24h	108.7	100.4	117.0	19.4	11.1	27.7
LPS Day 15	Overall	114.0	108.5	119.6	24.7	19.2	30.3
	2h	108.5	102.3	114.7	19.2	13.0	25.4
	4h	117.5	111.0	124.0	28.2	21.7	34.7
	10h	121.0	114.8	127.3	31.7	25.5	38.0
	24h	109.1	102.9	115.4	19.9	13.6	26.1
LPS Day 29	Overall	110.9	105.7	116.0	21.6	16.4	26.7
	2h	101.5	95.6	107.4	12.2	6.3	18.1
	4h	118.2	112.3	124.1	28.9	23.0	34.8
	10h	118.0	112.1	123.9	28.7	22.9	34.6
	24h	105.7	99.8	111.6	16.4	10.5	22.3

Analysis results LSCI Flare-1 Area (AU)							
Effect/Contrast	P-value	First LSM of contrast	Second LSM of contrast	Estimate of the difference	95% CI		
					Lower	Upper	
Prevalue	0.9236						
LPS Challenge Day	0.6354						
Time	<.0001						
Day by time	0.0399						
LPS Day 15 - LPS Day 1	0.6615	209.9	199.0	10.9	-42.6	64.3	
LPS Day 29 - LPS Day 1	0.7185	187.8	199.0	-11.2	-76.1	53.7	
LPS Day 29 - LPS Day 15	0.3619	187.8	209.9	-22.1	-72.8	28.7	
LPS Day 15 - LPS Day 1 at 10h	0.1339	261.8	216.5	45.3	-15.1	105.7	
LPS Day 29 - LPS Day 1 at 10h	0.6833	231.1	216.5	14.6	-57.9	87.0	
LPS Day 29 - LPS Day 15 at 10h	0.3077	231.1	261.8	-30.7	-91.2	29.8	
LPS Day 15 - LPS Day 1 at 24h	0.2049	183.7	145.7	38.0	-22.4	98.5	
LPS Day 29 - LPS Day 1 at 24h	0.9865	145.1	145.7	-0.6	-73.0	71.8	
LPS Day 29 - LPS Day 15 at 24h	0.2023	145.1	183.7	-38.6	-99.1	21.9	
95% CI							
Treatment	Time	LSM	Lower	Upper	LSM change from baseline	95% CI	
						Lower	Upper
LPS Day 1	Overall	199.0	147.5	250.6	154.6	103.0	206.1
	2h	207.5	153.5	261.6	163.1	109.0	217.1
	4h	226.4	172.3	280.4	181.9	127.9	235.9
	10h	216.5	162.5	270.6	172.1	118.0	226.1
	24h	145.7	91.7	199.8	101.3	47.2	155.3
LPS Day 15	Overall	209.9	182.8	237.0	165.4	138.4	192.5
	2h	166.6	132.7	200.6	122.2	88.2	156.2
	4h	227.4	191.4	263.4	182.9	146.9	218.9
	10h	261.8	227.9	295.8	217.4	183.4	251.4
	24h	183.7	149.7	217.7	139.3	105.3	173.2
LPS Day 29	Overall	187.8	143.9	231.7	143.4	99.5	187.3
	2h	153.6	103.9	203.3	109.1	59.5	158.8
	4h	221.5	171.8	271.2	177.0	127.4	226.7
	10h	231.1	181.4	280.8	186.7	137.0	236.3
	24h	145.1	95.4	194.8	100.7	51.0	150.3

Analysis results LSCI Mean Basal Flow (AU)							
Effect/Contrast	P-value	First LSM of contrast	Second LSM of contrast	Estimate of the difference	95% CI		
					Lower	Upper	
Prevalue	0.2150						
LPS Challenge Day	0.4913						
Time	<.0001						
Day by time	0.0898						
LPS Day 15 - LPS Day 1	0.5315	82.0	85.4	-3.4	-15.2	8.3	
LPS Day 29 - LPS Day 1	0.2429	78.6	85.4	-6.8	-18.8	5.3	
LPS Day 29 - LPS Day 15	0.4495	78.6	82.0	-3.3	-12.6	5.9	
LPS Day 15 - LPS Day 1 at 10h	0.3958	95.4	89.5	6.0	-8.2	20.1	
LPS Day 29 - LPS Day 1 at 10h	0.9780	89.3	89.5	-0.2	-14.9	14.5	
LPS Day 29 - LPS Day 15 at 10h	0.3103	89.3	95.4	-6.2	-18.3	6.0	
LPS Day 15 - LPS Day 1 at 24h	0.6786	74.5	71.6	2.9	-11.3	17.1	
LPS Day 29 - LPS Day 1 at 24h	0.6330	68.1	71.6	-3.5	-18.2	11.3	
LPS Day 29 - LPS Day 15 at 24h	0.2943	68.1	74.5	-6.4	-18.5	5.8	
95% CI							
Treatment	Time	LSM	Lower	Upper	LSM change from baseline	95% CI	
						Lower	Upper
LPS Day 1	Overall	85.4	74.6	96.3	30.6	19.7	41.4
	2h	87.6	75.6	99.6	32.8	20.8	44.8
	4h	93.0	81.0	105.0	38.2	26.2	50.2
	10h	89.5	77.5	101.4	34.6	22.6	46.6
	24h	71.6	59.6	83.5	16.7	4.7	28.7
LPS Day 15	Overall	82.0	75.5	88.5	27.1	20.6	33.6
	2h	71.9	63.8	80.0	17.1	9.0	25.1
	4h	86.1	78.0	94.2	31.3	23.2	39.3
	10h	95.4	87.4	103.5	40.6	32.5	48.6
	24h	74.5	66.4	82.5	19.6	11.5	27.7
LPS Day 29	Overall	78.6	70.9	86.4	23.8	16.0	31.6
	2h	70.4	60.9	80.0	15.6	6.0	25.1
	4h	86.9	77.3	96.4	32.0	22.5	41.5
	10h	89.3	79.7	98.8	34.4	24.9	43.9
	24h	68.1	58.5	77.6	13.2	3.7	22.8

2.2. Erythema by Antera 3D camera

Effect/Contrast	P-value	Analysis results Skin Colour (AU)				95% CI	
		First LSM of contrast	Second LSM of contrast	Estimate of the difference			
					Lower	Upper	
Prevalue	0.1102						
LPS Challenge Day	0.2305						
Time	<.0001						
Day by time	0.3560						
LPS Day 15 - LPS Day 1	0.6480	9.9	10.1	-0.2	-1.3	0.8	
LPS Day 29 - LPS Day 1	0.0956	9.1	10.1	-1.0	-2.2	0.2	
LPS Day 29 - LPS Day 15	0.1659	9.1	9.9	-0.8	-1.9	0.4	
LPS Day 15 - LPS Day 1 at 10h	0.5442	10.9	10.5	0.4	-1.0	1.9	
LPS Day 29 - LPS Day 1 at 10h	0.6261	10.1	10.5	-0.4	-1.9	1.2	
LPS Day 29 - LPS Day 15 at 10h	0.2459	10.1	10.9	-0.8	-2.2	0.6	
LPS Day 15 - LPS Day 1 at 24h	0.9663	9.1	9.1	0.0	-1.4	1.5	
LPS Day 29 - LPS Day 1 at 24h	0.5786	8.6	9.1	-0.4	-2.0	1.1	
LPS Day 29 - LPS Day 15 at 24h	0.5068	8.6	9.1	-0.5	-1.8	0.9	
95% CI							
Treatment	Time	LSM	Lower	Upper	LSM change from baseline	95% CI	
						Lower	Upper
LPS Day 1	Overall	10.1	9.2	11.0	3.0	2.1	3.9
	2h	10.3	9.2	11.5	3.2	2.1	4.4
	4h	10.6	9.5	11.8	3.5	2.4	4.7
	10h	10.5	9.3	11.6	3.4	2.3	4.6
	24h	9.1	7.9	10.2	2.0	0.8	3.1
LPS Day 15	Overall	9.9	9.1	10.7	2.8	2.0	3.6
	2h	9.0	8.1	10.0	1.9	1.0	2.9
	4h	10.5	9.6	11.4	3.4	2.5	4.4
	10h	10.9	10.0	11.8	3.8	2.9	4.8
	24h	9.1	8.2	10.0	2.0	1.1	2.9
LPS Day 29	Overall	9.1	8.2	10.0	2.0	1.1	3.0
	2h	8.3	7.3	9.4	1.3	0.2	2.3
	4h	9.3	8.2	10.4	2.2	1.2	3.3
	10h	10.1	9.0	11.2	3.0	2.0	4.1
	24h	8.6	7.6	9.7	1.5	0.5	2.6

Analysis results Haemoglobin Average Level (AU)							
Effect/Contrast	P-value	First LSM of contrast	Second LSM of contrast	Estimate of the difference	95% CI		
					Lower	Upper	
Prevalue	0.2827						
LPS Challenge Day	0.3393						
Time	<.0001						
Day by time	0.3008						
LPS Day 15 - LPS Day 1	0.9341	22.8	22.9	-0.1	-2.9	2.7	
LPS Day 29 - LPS Day 1	0.1713	20.4	22.9	-2.5	-6.1	1.2	
LPS Day 29 - LPS Day 15	0.1706	20.4	22.8	-2.4	-5.9	1.1	
LPS Day 15 - LPS Day 1 at 10h	0.4113	25.7	24.1	1.5	-2.2	5.2	
LPS Day 29 - LPS Day 1 at 10h	0.6966	23.3	24.1	-0.8	-5.1	3.4	
LPS Day 29 - LPS Day 15 at 10h	0.2522	23.3	25.7	-2.3	-6.4	1.7	
LPS Day 15 - LPS Day 1 at 24h	0.5694	20.9	19.8	1.0	-2.6	4.7	
LPS Day 29 - LPS Day 1 at 24h	0.6648	18.9	19.8	-0.9	-5.1	3.3	
LPS Day 29 - LPS Day 15 at 24h	0.3354	18.9	20.9	-1.9	-6.0	2.1	
95% CI							
Treatment	Time	LSM	Lower	Upper	LSM change from baseline	95% CI	
						Lower	Upper
LPS Day 1	Overall	22.9	20.5	25.3	7.9	5.5	10.3
	2h	23.2	20.4	26.0	8.2	5.3	11.0
	4h	24.4	21.6	27.2	9.4	6.5	12.2
	10h	24.1	21.3	27.0	9.1	6.3	12.0
	24h	19.8	17.0	22.7	4.8	2.0	7.6
LPS Day 15	Overall	22.8	20.7	24.8	7.8	5.7	9.8
	2h	20.4	17.8	23.0	5.4	2.8	8.0
	4h	24.2	21.6	26.8	9.2	6.6	11.8
	10h	25.7	23.1	28.2	10.6	8.1	13.2
	24h	20.9	18.3	23.5	5.9	3.3	8.4
LPS Day 29	Overall	20.4	17.3	23.5	5.4	2.3	8.5
	2h	18.3	15.1	21.6	3.3	0.0	6.6
	4h	21.1	17.8	24.4	6.1	2.8	9.4
	10h	23.3	20.0	26.6	8.3	5.0	11.6
	24h	18.9	15.6	22.2	3.9	0.6	7.2

2.3. Erythema grading score: Clinical Erythema Assessment (CEA)

Treatment and location	Time	Frequency Clinical Erythema Assessment			
		Clear	Almost Clear	Mild	Moderate
LPS Day 1: Site A	Pre	8 (100%)	0 (0%)	0 (0%)	0 (0%)
	10h	0 (0%)	2 (25%)	5 (63%)	1 (13%)
	24h	0 (%)	0 (%)	0 (%)	0 (%)
LPS Day 1: Site B	Pre	8 (100%)	0 (0%)	0 (0%)	0 (0%)
	10h	0 (0%)	1 (13%)	6 (75%)	1 (13%)
	24h	1 (13%)	1 (13%)	6 (75%)	0 (0%)
LPS Day 1: Site G	Pre	8 (100%)	0 (0%)	0 (0%)	0 (0%)
	10h	0 (0%)	0 (0%)	5 (63%)	3 (38%)
	24h	0 (%)	0 (%)	0 (%)	0 (%)
LPS Day 15: Site C	Pre	8 (100%)	0 (0%)	0 (0%)	0 (0%)
	10h	0 (0%)	4 (50%)	4 (50%)	0 (0%)
	24h	0 (%)	0 (%)	0 (%)	0 (%)
LPS Day 15: Site D	Pre	8 (100%)	0 (0%)	0 (0%)	0 (0%)
	10h	0 (0%)	2 (25%)	6 (75%)	0 (0%)
	24h	0 (0%)	3 (38%)	4 (50%)	1 (13%)
LPS Day 29: Site E	Pre	8 (100%)	0 (0%)	0 (0%)	0 (0%)
	10h	0 (0%)	1 (13%)	6 (75%)	1 (13%)
	24h	0 (%)	0 (%)	0 (%)	0 (%)
LPS Day 29: Site F	Pre	8 (100%)	0 (0%)	0 (0%)	0 (0%)
	10h	0 (0%)	2 (25%)	5 (63%)	1 (13%)
	24h	0 (0%)	4 (50%)	4 (50%)	0 (0%)

A:Upper back/Left(L) Upper(D) B:Upper back/Right(L) Upper(D) C:Upper back/Left(L) Middle(D)
 D:Upper back/Right(L) Middle(D) E:Upper back/Left(L) Bottom(D) F:Upper back/Right(L) Bottom(D)
 G:Forearm/Right(L) Volar(D); L=Lateral; D=Directional
 No scores taken at 24h for sites A,C,E and G

3. Blister exudate analysis

3.1. Neutrophils and monocyte subsets

Analysis results LOG Amount of CD16+ CD66+ Neutrophils (cells)

Effect/Contrast	P-value	Back Transformed			95% CI	
		First LSM of contrast	Second LSM of contrast	Estimate of the difference	Lower	Upper
LPS Challenge Day	0.6145					
Time	0.0008					
Day by time	0.1431					
LPS Day 15 - LPS Day 1	0.4491	25.7	52.2	-50.7%	-93.0%	248.6%
LPS Day 29 - LPS Day 1	0.3720	24.9	52.2	-52.4%	-91.5%	167.0%
LPS Day 29 - LPS Day 15	0.9720	24.9	25.7	-3.3%	-87.4%	641.9%
LPS Day 15 - LPS Day 1 at 10h	0.0803	38.5	286.3	-86.6%	-98.6%	30.4%
LPS Day 29 - LPS Day 1 at 10h	0.1958	70.9	286.3	-75.2%	-97.2%	116.7%
LPS Day 29 - LPS Day 15 at 10h	0.6228	70.9	38.5	84.4%	-85.5%	2238.7%
LPS Day 15 - LPS Day 1 at 24h	0.5929	17.2	9.5	80.9%	-81.4%	1655.8%
LPS Day 29 - LPS Day 1 at 24h	0.9270	8.7	9.5	-8.4%	-87.0%	546.0%
LPS Day 29 - LPS Day 15 at 24h	0.5574	8.7	17.2	-49.3%	-95.3%	441.2%
Back Transformed						
Treatment	Time	LSM		Lower	Upper	
LPS Day 1	Overall	52.2	14.8	183.9		
	10h	286.3	73.1	1120.9		
	24h	9.5	2.4	37.3		
LPS Day 15	Overall	25.7	4.6	144.1		
	10h	38.5	5.4	274.1		
	24h	17.2	2.4	122.7		
LPS Day 29	Overall	24.9	6.0	102.4		
	10h	70.9	11.4	443.0		
	24h	8.7	1.9	41.1		

Analysis results LOG Amount of classical monocytes (CD14+ CD16-) (cells)

Effect/Contrast	P-value	Back Transformed			95% CI	
		First LSM of contrast	Second LSM of contrast	Estimate of the difference	Lower	Upper
LPS Challenge Day	0.1261					
Time	0.4437					
Day by time	0.1169					
LPS Day 15 - LPS Day 1	0.0543	128.0	279.4	-54.2%	-79.4%	1.7%
LPS Day 29 - LPS Day 1	0.1452	127.3	279.4	-54.5%	-84.8%	36.8%
LPS Day 29 - LPS Day 15	0.9912	127.3	128.0	-0.6%	-66.9%	199.2%
LPS Day 15 - LPS Day 1 at 10h	0.0053	85.8	566.5	-84.8%	-95.7%	-46.4%
LPS Day 29 - LPS Day 1 at 10h	0.1060	155.8	566.5	-72.5%	-94.4%	35.0%
LPS Day 29 - LPS Day 15 at 10h	0.4759	155.8	85.8	81.5%	-67.0%	898.4%
LPS Day 15 - LPS Day 1 at 24h	0.5986	190.9	137.8	38.5%	-60.9%	390.4%
LPS Day 29 - LPS Day 1 at 24h	0.6776	104.0	137.8	-24.5%	-81.2%	202.3%
LPS Day 29 - LPS Day 15 at 24h	0.4175	104.0	190.9	-45.5%	-88.1%	149.7%

Back Transformed

Treatment	Time	LSM	95% CI	
			Lower	Upper
LPS Day 1	Overall	279.4	150.1	520.0
	10h	566.5	254.9	1259.3
	24h	137.8	62.0	306.4
LPS Day 15	Overall	128.0	68.2	240.2
	10h	85.8	29.7	248.4
	24h	190.9	66.0	552.4
LPS Day 29	Overall	127.3	46.2	350.8
	10h	155.8	36.6	662.8
	24h	104.0	31.0	348.4

Analysis results LOG Amount of intermediate monocytes (CD14+ CD16+) (cells)

Effect/Contrast	P-value	Back Transformed			95% CI	
		First LSM of contrast	Second LSM of contrast	Estimate of the difference	Lower	Upper
LPS Challenge Day	0.4470					
Time	0.9514					

Day by time	0.1328					
LPS Day 15 - LPS Day 1	0.3562	10.6	20.3	-47.8%	-87.9%	125.1%
LPS Day 29 - LPS Day 1	0.2418	7.8	20.3	-61.8%	-93.0%	109.1%
LPS Day 29 - LPS Day 15	0.7109	7.8	10.6	-26.9%	-87.7%	333.8%
LPS Day 15 - LPS Day 1 at 10h	0.0406	5.1	35.6	-85.7%	-97.8%	-8.6%
LPS Day 29 - LPS Day 1 at 10h	0.1672	8.8	35.6	-75.2%	-96.7%	87.7%
LPS Day 29 - LPS Day 15 at 10h	0.5909	8.8	5.1	73.4%	-78.7%	1310.1%
LPS Day 15 - LPS Day 1 at 24h	0.4801	22.1	11.6	90.7%	-70.2%	1119.4%
LPS Day 29 - LPS Day 1 at 24h	0.5698	6.8	11.6	-41.2%	-91.3%	298.1%
LPS Day 29 - LPS Day 15 at 24h	0.2316	6.8	22.1	-69.2%	-95.8%	125.3%

Treatment	Time	LSM	Back Transformed	
			Lower	Upper
LPS Day 1	Overall	20.3	7.1	58.0
	10h	35.6	9.6	132.0
	24h	11.6	3.1	42.9
LPS Day 15	Overall	10.6	3.1	35.8
	10h	5.1	1.2	21.6
	24h	22.1	5.2	93.9
LPS Day 29	Overall	7.8	1.7	35.7
	10h	8.8	1.6	47.5
	24h	6.8	1.4	32.1

Analysis results LOG Amount of non classical monocytes (CD14- CD16+) (cells)						
Effect/Contrast	P-value	First LSM of contrast	Second LSM of contrast	Estimate of the difference	Back Transformed	
					Lower	Upper
LPS Challenge Day	0.1363					
Time	0.0254					
Day by time	0.2579					
LPS Day 15 - LPS Day 1	0.1023	6.2	16.4	-62.2%	-88.6%	24.8%
LPS Day 29 - LPS Day 1	0.0758	5.9	16.4	-64.1%	-88.6%	12.9%
LPS Day 29 - LPS Day 15	0.9346	5.9	6.2	-4.9%	-73.6%	243.2%

LPS Day 15 - LPS Day 1 at 10h	0.0194	6.3	44.6	-85.9%	-97.2%	-29.2%
LPS Day 29 - LPS Day 1 at 10h	0.0452	9.3	44.6	-79.1%	-95.5%	-3.6%
LPS Day 29 - LPS Day 15 at 10h	0.5993	9.3	6.3	48.6%	-68.1%	592.7%
LPS Day 15 - LPS Day 1 at 24h	0.9849	6.1	6.0	1.5%	-79.8%	411.3%
LPS Day 29 - LPS Day 1 at 24h	0.5033	3.7	6.0	-38.2%	-85.7%	167.4%
LPS Day 29 - LPS Day 15 at 24h	0.4920	3.7	6.1	-39.1%	-86.1%	166.3%

Treatment	Time	LSM	Back Transformed	
			Lower	Upper
LPS Day 1	Overall	16.4	7.3	36.8
	10h	44.6	13.5	147.2
	24h	6.0	1.8	19.9
LPS Day 15	Overall	6.2	2.2	17.4
	10h	6.3	1.9	21.2
	24h	6.1	1.8	20.7
LPS Day 29	Overall	5.9	2.3	15.4
	10h	9.3	3.2	27.6
	24h	3.7	1.4	10.0

Adverse events

Summary of Number of Subjects with TEAEs by Treatment SOC and PT								
System Organ Class/ Preferred Term	LIPOPOLYSACCHARIDE CHALLENGE 1 (N=9)		LIPOPOLYSACCHARIDE CHALLENGE 2 (N=8)		LIPOPOLYSACCHARIDE CHALLENGE 3 (N=8)		All Subjects (N=9)	
	Subjects N (%)	Events N	Subjects N (%)	Events N	Subjects N (%)	Events N	Subjects N (%)	Events N
ANY EVENTS	3 (33.3%)	6	3 (37.5%)	3	3 (37.5%)	3	6 (66.7%)	12
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	1 (11.1%)	1	0	0	0	0	1 (11.1%)	1
INFLUENZA LIKE ILLNESS	1 (11.1%)	1	0	0	0	0	1 (11.1%)	1
INFECTIONS AND INFESTATIONS	1 (11.1%)	1	2 (25.0%)	2	1 (12.5%)	1	3 (33.3%)	4
HERPES ZOSTER	1 (11.1%)	1	0	0	0	0	1 (11.1%)	1
NASOPHARYNGITIS	0	0	2 (25.0%)	2	1 (12.5%)	1	2 (22.2%)	3
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	1 (11.1%)	1	0	0	0	0	1 (11.1%)	1
MYALGIA	1 (11.1%)	1	0	0	0	0	1 (11.1%)	1
NERVOUS SYSTEM DISORDERS	0	0	1 (12.5%)	1	1 (12.5%)	1	2 (22.2%)	2
HEADACHE	0	0	1 (12.5%)	1	0	0	1 (11.1%)	1
PRESYNCOPE	0	0	0	0	1 (12.5%)	1	1 (11.1%)	1
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	1 (11.1%)	2	0	0	0	0	1 (11.1%)	2
HAEMOPTYSIS	1 (11.1%)	1	0	0	0	0	1 (11.1%)	1
OROPHARYNGEAL PAIN	1 (11.1%)	1	0	0	0	0	1 (11.1%)	1
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	1 (11.1%)	1	0	0	1 (12.5%)	1	2 (22.2%)	2
PRURITUS	1 (11.1%)	1	0	0	0	0	1 (11.1%)	1
SENSITIVE SKIN	0	0	0	0	1 (12.5%)	1	1 (11.1%)	1

SOC: System Organ Class, PT: Preferred Term, TEAE: Treatment Emergent Adverse Event